Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension CIRCULATION RESEARCH Rabinovitch, M., Guignabert, C., Humbert, M., Nicolls, M. R. 2014; 115 (1): 165-175

Abstract

This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension. The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed. Pre-clinical studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed. In addition, we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development. We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.

View details for DOI 10.1161/CIRCRESAHA.113.301141

View details for Web of Science ID 000337738900018

View details for PubMedID 24951765